Related to BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe

• Otsuka’s Vasopressin Agonist Approved in Europe for Hyponatremia
  
• Novartis’ Afinitor Receives EU Sanction for Advanced RCC After Failed Anti-VEGF Therapy
  
• EMEA Issues Treatment Recommendations to Preserve Supply of Genzyme’s Gaucher’s Drug
  
• BioAlliance Gets Swiss Regulatory Okay for Oral Candidasis Drug
  
• European Commission Clears Wyeth Drug for Relapsed and Refractory Mantle Cell Lymphoma
  
• Santhera Implements Named Patient Program for Friedrich’s Ataxia Drug in Europe and Switzerland
  
• Gene Involved in Energy Consumption Is Epigenetically Modified in Type 2 Diabetics
  
• Germany Sanctions MediGene’s Topical Treatment for Genital Warts
  
• Fast EU Approval of Baxter’s H1N1 Flu Vaccine Enabled by EMEA’s Mock-Up Licensure Process
  
• Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication
  
• Sanofi-Aventis Inks $350M Deal for Wellstat’s Phase II Therapy for Type 2 Diabetes
  
• EU Speeds Approval of Novartis’ mAb for CAPS in Adults and Children
  
• Germany Sanctions Novartis’ Cell Culture-Based H1N1 Flu Vaccine
  
• Tethys Secures $25M to Expand Reach of Type 2 Diabetes Test
  
• French Authorities Approve Six-Month Formulation of Debiopharm and Ipsen’s Prostate Cancer Drug
  
• Spherix’ Preliminary Late-Stage Data Bodes Well for Oral Antidiabetic
  
• The Medicines Company Receives Label Expansion for Anticoagulant
  
• EU Sanctions Novartis’ Once-Daily Inhaled Therapy for COPD
  
• EU Gives Dynavax’ German Manufacturing Plant the Nod for Commercial Production of HBV Vaccine
  
• EC Gives Pfizer’s 13-Valent Pneumococcal Vaccine the Nod for Use in Children